TAKEDA Pharmaceuticals Australia have notified the TGA that its Vyvanse 20mg capsules are now in shortage.
It is also expected that from late Aug, Vyvanse 60mg caps will be in limited supply.
These shortages are due to higher-than-normal demand for these strengths of Vyvanse capsules, used to treat conditions such as attention deficit hyperactivity and binge eating disorders.
Takeda stated it is working closely with pharmacy wholesalers to facilitate equitable distribution of available strengths.
Pharmacists should advise their patients to contact their doctors to arrange another treatment option.
The above article was sent to subscribers in Pharmacy Daily's issue from 20 Jun 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 20 Jun 24
